{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-042630","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2024-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.836482+00:00","generated_at":"2026-05-30T16:50:02.293642+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Foghorn Therapeutics announces first patient dosed with FHD-909 in Phase 1 trial for SMARCA4 mutated cancers","bullets":["First patient dosed with FHD-909 (LY4050784), a first-in-class oral SMARCA2 selective inhibitor, in Phase 1 trial for SMARCA4 mutated solid tumors.","Primary target patient population is non-small cell lung cancer (NSCLC).","Lilly leads clinical development under a U.S. 50/50 co-development and co-commercialization collaboration with Foghorn.","Preclinical studies showed robust anti-tumor monotherapy activity and favorable tolerability in SMARCA2 mutant xenograft models."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-042630","json":"https://secwatch.observer/filing/0001628280-24-042630.json","markdown":"https://secwatch.observer/filing/0001628280-24-042630.md","text":"https://secwatch.observer/filing/0001628280-24-042630.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024042630/0001628280-24-042630-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024042630/fhtx-20241010.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T16:50:02.293642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}